Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53

Basal/human epidermal growth factor receptor (HER)2-positive (HER2+) breast cancer is resistant to monoclonal antibody (herceptin) treatment. There are currently only three basal/HER2+ breast cancer cell lines...

Source: Cancer Cell International - August 17, 2018 Category: Cancer & Oncology Authors: Fei Zhou, Yanhua Zhang, Xiufang Xu, Jingfeng Luo, Fang Yang, Linbo Wang, Shuduo Xie, Jihong Sun and Xiaoming Yang Tags: Primary research Source Type: research